Difference between revisions of "Prostate cancer staging"

Jump to navigation Jump to search
Line 84: Line 84:
*Immunostains useful to separate prostate carcinoma from [[SV]] are discussed in the ''[[seminal vesicle]]'' article.
*Immunostains useful to separate prostate carcinoma from [[SV]] are discussed in the ''[[seminal vesicle]]'' article.
*It is not possible to differentiate the ''seminal vesicles'' and ''ejaculatory ducts'' based only on histology; thus, on biopsy one can generally comment only on ''seminal vesicle/ejaculatory duct invasion''.
*It is not possible to differentiate the ''seminal vesicles'' and ''ejaculatory ducts'' based only on histology; thus, on biopsy one can generally comment only on ''seminal vesicle/ejaculatory duct invasion''.
*SVI has been subdivided into three types (type I: spread along ejaculatory duct complex, type II: through prostate capsule and then into SV; type III: discontinuous spread/metastasis).<ref name=pmid16985773>{{Cite journal  | last1 = Potter | first1 = SR. | last2 = Epstein | first2 = JI. | last3 = Partin | first3 = AW. | title = Seminal vesicle invasion by prostate cancer: prognostic significance and therapeutic implications. | journal = Rev Urol | volume = 2 | issue = 3 | pages = 190-5 | month =  | year = 2000 | doi =  | PMID = 16985773 }}</ref>


===Lymph node===
===Lymph node===
48,454

edits

Navigation menu